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Abstract
Background: Plasmodium and Schistosoma are two of the most common parasites in tropical areas. Deregulation
of the immune response to Plasmodium falciparum, characterized by a Th1 response, leads to cerebral malaria
(CM), while a Th2 response accompanies chronic schistosomiasis.
Methods: The development of CM was examined in mice with concomitant Schistosoma mansoni and Plasmodium
berghei ANKA infections. The effect of S. mansoni egg antigen injection on disease development and survival was
also determined. Cytokine serum levels were estimated using ELISA. Statistical analysis was performed using t-test.
Results: The results demonstrate that concomitant S. mansoni and P. berghei ANKA infection leads to a reduction
in CM. This effect is dependent on infection schedule and infecting cercariae number, and is correlated with a Th2
response. Schistosomal egg antigen injection delays the death of Plasmodium-infected mice, indicating immune
involvement.
Conclusions: This research supports previous claims of a protective effect of helminth infection on CM
development. The presence of multiple parasitic infections in patients from endemic areas should therefore be
carefully noted in clinical trials, and in the development of standard treatment protocols for malaria. Defined
helminth antigens may be considered for alleviation of immunopathological symptoms.
Background
Malaria, an infectious disease caused by the Plasmodium
parasite, is a source of enormous morbidity and mortal-
ity. Cerebral malaria (CM), seen in about 7% of Plasmo-
dium falciparum malaria cases, is characterized by the
presence of neurological features, especially impaired
consciousness [1]. The simplified explanation for CM
pathogenesis is adherence and sequestration of parasi-
tized erythrocytes, immune cells and platelets to vascu-
lar endothelial cells lining the small blood vessels of the
brain. Thus, parasite-triggered cerebral inflammation is
a possible cause of death from CM [2]. The immune
response is critical in determining the outcome of infec-
tion [2]. CM is characterized by a Th1 response, with
overproduction of some cytokines (e.g. interferon-g,
IFNg), combined with underproduction of others (e.g.
interleukin-10, IL-10) [3].
By analogy with the inhibition of autoimmune disease
development by helminthic infections [4], it has been
demonstrated, both in murine studies and in humans,
that concomitant helminth infection may change the
course of Plasmodium infection [5,6].
Schistosomes are parasitic trematodes found in sub-
tropical and tropical areas. Among human parasitic dis-
eases, schistosomiasis ranks second behind malaria in
terms of socio-economic and public health importance.
In many areas of the world, schistosomiasis and malaria
are co-endemic: shared antigens and cross-reactive anti-
bodies to different components of the two parasites
have been detected [7]. Chronic helminthic infections
are established through modulation of the host immune
system. In schistosomal infection, each pair of male and
female worms produces hundreds of eggs per day; egg-
associated glycolipids and glycoproteins are the main
target of the host humoral immune response [8]. In
schistosomiasis, the early phase of infection is character-
ized by Th1 immune responses, which progress to a
Th2 response. This pattern of cytokine expression is
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also found in non-cerebral (severe anaemic) malaria. In
contrast, CM results from a predominantly Th1
response [9]. In schistosomiasis, the Th2-type responses
are driven by schistosome egg antigens (SEAs) with
intact carbohydrate moieties [10]. A major secretory gly-
coprotein, the IL-4-inducing principle from schistosome
eggs IPSE (also known as alpha-1, or IPSE/alpha-1) [11],
was identified as the bioactive component in Schisto-
soma mansoni egg extracts [12]. IPSE/alpha-1 triggers
basophils to release IL-4, leading to subsequent IL-13
and additional IL-4 expression, the latter cytokine being
a potential key player in Th2 biasing [8].
Several studies in murine models demonstrate a non-
consistent effect of Schistosoma infection on malaria
development, which is mostly expressed as enhancement
of parasitaemia [13]. Similar conclusions concerning
human malaria are based on study cases in endemic
areas [14]. This research examined the effect of a pre-
existing schistosomal infection on the development of
murine CM, and the possible role of a main schistoso-
mal antigen, IPSE/alpha-1, in the effect seen. The results
demonstrate that IPSE/alpha-1 has a role in changing
the course of malaria infection, leading to increased sur-
vival, and that a shift in cytokine expression is asso-
ciated with CM reduction. Overall, this research




Schistosoma mansoni cercariae and schistosomula: an
Egyptian strain of S. mansoni, kept in Puerto Rican
Biomphalaria glabrata snails and ICR mice, was used
throughout this work. Cercaria shedding was induced by
subjecting infected, water-immersed snails to light for
1.5 hours. The cercariae were concentrated by cooling
and low speed centrifugation.
The ANKA strain of Plasmodium berghei (MRA-311,
CDC, Atlanta) was maintained in vivo by serial transfer
of parasitized erythrocytes from infected to naive mice.
Hosts
ICR HSD (Harlan-Sprague-Dawley) male mice aged six
to seven weeks were used in all experiments; eight to 10
mice per group. The mice were housed under standard
light and temperature conditions and were provided
with unlimited access to water and food. The experi-
ments were carried out in accordance with institutional
guidelines for animal care, by a protocol approved by
the Animal Ethical Care Committee of The Hebrew
University of Jerusalem, AAALAC (Association for
Assessment and Accreditation of Laboratory Animal
Care) accreditation number #1285. The choice of geneti-
cally heterogenous mice was made in order to enable a
more accurate reflection of CM susceptibility and the
possible effect of coinfection in human beings. The
validity of the CM model in outbred mice has previously
been demonstrated [15]
Experimental setup
Mice were infected with 50 or 100 S. mansoni cercariae
by subcutaneous injection. Four or seven weeks later,
one group of each condition was infected with 5 × 104
P. berghei-parasitized red blood cells, an inoculum
which leads to cerebral malaria in the majority of
infected mice. Additional control groups consisted of
mice infected with P. berghei or S. mansoni only. Worm
burdens were determined by dissection of Schistosoma-
infected mice. Alternatively, mice were first infected
with P. berghei and subsequently administered complete
S. mansoni egg extract (SmEA) [12], egg extract from
which IPSE/alpha-1 was removed (SmEA ΔIPSE/alpha-
1) [16] (45 μg/mouse/day on days -7, 0, and 3 post-
infection; 22.5 μg/mouse on day 6 post-infection), or
IPSE/alpha-1 [8,11] (5 μg/mouse/day from day -7 to +4
post-infection), by intravenous (iv) administration. Para-
sitaemia was monitored every other day by thin blood
smears prepared from tail blood. These were stained
with a Giemsa solution and examined under a light
microscope. Blood samples were taken for subsequent
cytokine analysis by ELISA (Biolegend, Israel). The mini-
mum detectable concentrations were 4 pg/ml, 2 pg/ml,
1 pg/ml, and 30 pg/ml for IFNg, TNF, IL-4, and IL-10,
respectively.
The link between immune responses, death and cere-
bral malaria in mouse models has previously been
demonstrated [2]. Observed clinical symptoms, including
an accelerated drop in temperature and death at low
parasitaemia, indicate CM [17]. Parasitaemia levels, the
appearance of neurological symptoms and changes in
weight, temperature, and haematocrit of infected mice
were evaluated. Clinical signs, which appear one to two
days before death from CM, include marked coat star-
ing, hunching, wobbly gait and reduced locomotion,
convulsions, and coma. Brain pathology observed in
mice dying of CM includes haemorrhages, mononucu-
lear cell infiltrations and the development of brain
oedema (Figure 1). Mice that died at a parasitaemia of
up to 15% with accompanying neurological symptoms,
drastic weight reduction, and a body temperature of 34°
C or below were considered to have died of CM. Mice
which did not die from CM died from severe malaria-
induced anaemia and high parasitaemia, as has been
reported in all other cases where mice do not succumb
to P. berghei-induced CM [18].
Histology
Brains of non-infected and PbA-infected moribund mice
were taken for histological examination. Mice were dee-
ply anaesthetized and sacrificed by intracardial perfusion
with 10 ml ice-cold PBS. Brains were removed, fixed in
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Figure 1 Brain histology of non-infected and PbA-infected ICR mice. Brains were removed from control non-infected mice (n = 10) or PbA-
infected moribund mice (n = 10) on day 8 post- PbA inoculation. Representative sections are shown for each group. (A) Representative section
of the cortex of a control mouse, demonstrating lack of vessel distention or pathology (magnification 20×). (B) Representative section of the
submeningeal cortex of a control mouse, demonstrating the lack of haemorrhages or cellular infiltrations (magnification 10×). (C) Mononuclear
cell aggregation in a meningeal vessel, increased cellularity, and piknotic nuclei in a prostrate mouse (magnification 20×). (D) Distended
thallamic blood vessel; mononuclear cell interacting with activated endothelial cells (boxed) in a prostrate mouse (magnification 40×). (E)
“Spongy” tissue - evidence of edema in a PbA-infected mouse suffering from coma (magnification 40×). (F) Meningeal haemorrahges in a PbA-
infected mouse suffering from coma (magnification 10×).
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a 4% formaldehyde solution, and embedded in paraffin.
Paraffin-embedded tissues were cut into 5 μm slices,
deparaffinated, and stained with haematoxylin and eosin
(H&E) before coverslipping, according to standard
procedure.
Statistics
p values were calculated using Students t-test.
Results
Two different infection schedules were examined, in
order to determine how long after worm infection a
protective effect against CM may be seen. Mice were
divided into four groups, two of which were infected
with P. berghei four or seven weeks after injection of
100 S. mansoni cercariae. The remaining two groups
served as controls for S. mansoni or P. berghei infection.
In mice co-infected four weeks post-S. mansoni infec-
tion, no significant effect was seen on body temperature,
weight loss (Figure 2A), or CM (60% in co-infected vs.
70% in P. berghei-infected mice). In contrast, when mice
were co-infected seven weeks after cercariae injection, a
protective effect of the pre-existing S. mansoni infection
Figure 2 Changes in temperature and body weight, and survival of mice infected with PbA 4 weeks (A), or 7 weeks (B) after S.
mansoni infection, and in corresponding PbA- and S. mansoni infected control mice. Weight and temperature were monitored until days
9-11, when most of the deaths in the PbA-infected groups occurred. Error bars represent SD. *p < 0.001 (t-test), co-infected vs. S. mansoni and
PbA-infected groups; §p < 0.0001 (t-test), PbA- vs. co-infected mice; **p < 0.002 (t-test), co-infected vs. PbA-infected mice.
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was seen: co-infected mice displayed lower rates of CM
(30% vs. 60% in control mice), correlated to higher body
temperatures and weights, and a delay to death (Figure
2B). The haematocrit of co- and S. mansoni- infected
mice was similar (an average of 53 and 54 on day 3; 47
and 49 on day 7 after P. berghei infection, respectively),
while the haematocrit of P. berghei-infected mice
dropped from an average 51 on day 3 to 39 on day 7
after infection. Worm loads in the S. mansoni control
group were examined four or seven weeks post-infec-
tion. Worm loads were not detectable four weeks after
cercariae injection. Worm loads in mice co-infected
seven weeks post-S. mansoni infection were found to be
slightly lower than in mice infected with S. mansoni
only (17.6 ± 2.3 vs. 22.6 ± 7.3, worms, respectively).
Equal numbers of male and female worms were seen in
each mouse.
The next experiment was planned to evaluate the
effect of cercarial dose on the malarial infection. As
shown (Figure 3), P. berghei infection led to CM in five
of eight control mice (63%); the remaining mice died of
severe anaemic malaria. Two of six mice (33%) co-
infected with 50 cercariae died of CM. Infection with
100 cercariae, however, prevented cerebral malaria in all
7 co-infected mice (Table 1, Experiment 1, 100 cercar-
iae). No significant differences in parasitaemia were seen
during the first 11 days of infection, the time period in
which death from CM occurs. On day 7 post-infection,
the average haematocrit in the co-infected group was 49
± 9, compared to 39 ± 3 in the P. berghei-infected
group and 49 ± 3 in the S. mansoni group, indicating
the absence of severe anaemia. A delay in time of death
was observed in the S. mansoni-infected groups relative
to the control group: on day 13 post-infection the
majority of control mice were dead, whereas 66% of
mice injected with 50 cercariae, and all of the mice
injected with 100 cercariae were still alive. On day 9, P.
berghei-infected mice had lost an average 15 ± 2% of
their initial body weight, while co-infected mice lost 24
± 5%. This result may be attributed to the high parasite
burden in the co-infected mice. In comparison, mice
infected solely with S. mansoni gained an average 2 ±
6% body weight during this period. None of the mice
infected solely with S. mansoni died, indicating that
pathology due to the helminth infection was not a cause
of death in these experiments. Each experiment was
repeated (Table 1). Overall, the results indicate that S.
mansoni infection provides protection against CM.
Serum cytokine profiles were determined at several
time points in mice co-infected with P. berghei seven
weeks after injection of 100 S. mansoni cercariae (days
1, 7, and 10 post-P. berghei infection). Control groups
included non-infected mice and mice infected with S.
mansoni or P. berghei only (Figure 4). On day 1, an
increase in serum IFNg was seen in P. bergheiinfected
mice (p < 0.05), while no significant increase in IFNg
levels was seen in co-infected mice. IFNg levels were
below detection in non-infected and S. mansoni-infected
mice. Although TNF levels rose slightly in the PbA- and
co-infected groups, this change was not statistically sig-
nificant. Co-infected mice displayed higher IL-4 relative
to both non-infected and PbA-infected mice (p < 0.05).
IL-10 levels were similar in S. mansoni- and non-
infected mice; co-infected mice displayed higher IL-10
compared to P. berghei-infected mice (p < 0.05). The
difference in IL-10 levels between PbA- and S. mansoni-
infected mice was significant (p < 0.01). By day 7, IFNg
levels had risen significantly in P. berghei- and co-
infected mice, compared to non-infected mice (p < 0.05)
and S. mansoni-infected mice (p < 0.01). Although no
statistically significant differences in IFNg were seen
when comparing PbA- and co-infected mice, the
Table 1 The effect of S. mansoni infection on the development of cerebral malaria.
50 cercariae P. berghei-infected mice Co-infected mice*
Cerebral malaria Anaemic malaria Cerebral malaria Anaemic malaria
Experiment 1 5 3 2 4
Experiment 2 7 3 2 9
Total 12/18 6/18 4/17 13/17
(%) (67%) (33%) (24%) (76%)
100 cercariae P. berghei-infected mice Co-infected mice*
Cerebral malaria Anaemic malaria Cerebral malaria Anaemic malaria
Experiment 1 5 3 0 7
Experiment 2 7 3 3 7
Experiment 3 6 5 2 8
Total 18/29 11/29 5/27 22/27
(%) (62%) (38%) (19%) (81%)
* Mice were infected with 5 × 104 P. berghei-parasitized erythrocytes seven weeks after injection of 50 or 100 S. mansoni cercariae.
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difference in TNF was significant (p < 0.05). Co-infected
mice showed a dramatic rise in IL-4 (p < 0.05); this rise
in serum IL-4 (day 7 compared to day 1, corresponding
to days 42 and 36 of S. mansoni infection) is presumably
due to an egg-induced Th2 response. IFNg was higher in
P. berghei- and co-infected mice compared to the S.
mansoni-infected group (p < 0.01, p < 0.05, respectively),
and TNF was raised in co-infected mice compared to
the S. mansoni-infected group (p < 0.05). These differ-
ences are presumably due to the ongoing inflammatory
response caused by the malaria parasites. On day 10, no
significant differences in IFNg were seen when compar-
ing PbA- to S. mansoni-or co-infected mice, or between
S. mansoni- and co-infected mice. Differences in IL-10
were significant (p < 0.05) when comparing co-infected
and S. mansoni- or PbA-infected mice. TNF levels were
higher in co-infected vs S. mansoni-infected mice. No
significant differences in IL-4 were seen between the
groups.
The overall immune response in the different groups
may be summarized using the ratio between the Th1-
Figure 3 The effect of S. mansoni infection on the development
of cerebral malaria in ICR mice. Mice infected with 5 × 104 PbA-
infected erythrocytes (A), 5 × 104 PbA-infected erythrocytes, seven
weeks after injection of 50 S. mansoni cercariae (B), or 5 × 104 PbA-
infected erythrocytes, seven weeks after injection of 100 S. mansoni
cercariae (C). Each line represents one mouse; D notes mouse death.
Co-infection of mice with 100 cercariae caused a significant
reduction in cerebral malaria (p < 0.0001, t-test). Shaded areas
denote the period of CM susceptibility and death.
Figure 4 Average serum cytokine levels (pg/ml) ± SD in
infected and non-infected ICR mice (n = 5 at each time point).
Mice were infected with PbA 7 weeks after S. mansoni infection.
Cytokine levels were measured on day 1 (A), day 7 (B), and day 10
post-PbA infection (C).
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and Th2-group cytokines examined (Figure 5). IL-4 and
IL-10 are signature Th2 cytokines; IL-4 is critically
involved in biasing the immune reaction toward a Th2
phenotype. In mice which develop severe anaemic
malaria, a transient early rise in IFNg typically occurs,
while in mice which develop CM, IFNg levels remain
high as the result of immune deregulation [2]. The
results show that P. berghei infection caused an immedi-
ate, significant shift in the Th response of infected mice:
both P. berghei-infected and co-infected groups showed
skewing towards a Th1-type response when cytokine
ratios were compared to non- or S. mansoni-infected
mice (p < 0.01, p < 0.05, respectively). However, on day
7, P. berghei-infected mice still showed a clear Th1 shift,
compared to non-infected and S. mansoni-infected mice
(p < 0.01); co-infected mice displayed a prevalently Th2
response (p < 0.05). On day 10, the difference in Th1
response in P. berghei- vs. S. mansoni-infected mice was
still apparent (p < 0.05), but no difference was seen
when comparing P. berghei- and co-infected mice. Over-
all, the results hint at a Th2 shift caused by the pre-
existing schistosomal infection.
Our next step was to examine the effect of IPSE/
alpha-1 administration and injection of intact or IPSE/
alpha-1-depleted egg extract, on the course of P. berghei
infection. Two protocols were used to determine the
effect of IPSE/alpha-1 on CM. In the first experiment, 5
μg/mouse IPSE/alpha-1 was injected i.v. from day -4 to
day +7 post-infection. Although antigen injection did
not improve the rate of CM (50% of control and 75% of
treated mice; Figure 6A), a significant delay in death
was seen. The median survival was 15 days among trea-
ted mice, compared to 8 days in the control group (Fig-
ure 6B). In order to verify the role of IPSE/alpha-1 on
the course of the disease, mice were injected with SmEA
or SmEA ΔIPSE/alpha-1. Both extracts were adminis-
tered by i.v. injection at a dose of 45 μg/mouse on days
-7, 0 and +3 followed by 22.5 μg/mouse on day +6 post-
infection. Administration of SmEA had a slight effect on
CM development, as did SmEA ΔIPSE/alpha-1 injection
(Figure 7), with the rate of CM dropping from 90% in
the control group to 70% and 80%, respectively. As in
the previous experiments, IPSE/alpha-1 delayed mouse
death. The complete extract was more effective than the
extract lacking IPSE/alpha-1 (Figure 7).
Discussion
In malaria-endemic areas, infections caused by intestinal,
schistosomal or filarial parasites commonly coexist with
malaria in the same patient [19,20]. There has been
much speculation as to an immunological aspect of the
effect of schistosomes, which induce a host Th2
response [21], on malaria parasites.
In the present study, we investigated the effect of schis-
tosomal parasites or their antigens on the development
of the Th1-associated cerebral malaria, using the estab-
lished procedure for murine CM induction. As S. man-
soni affects mainly the liver, and Plasmodium infects
hepatocytes prior to infection of the red blood cells, a
more accurate experimental setup would have been to
Figure 5 Average Th2-Th1 ratio. The balance between Th1 and Th2 responses was determined using the cytokine levels of each mouse, as
follows: Th2/Th1 ratio = (sum of IL-4 and IL-10 levels) - (sum of IFNg and TNF levels). Average values ± SD are presented per day. p < 0.05 (t-
test) when comparing *non-infected and S. mansoni-infected mice; **non-infected and PbA-infected mice; †S. mansoni- and PbA-infected mice;
‡S. mansoni- and co-infected mice; §PbA- and co-infected mice.
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use the full plasmodial life cycle, i.e. starting from infec-
tion of the mice by the bite of infected mosquitoes. In
case of a full-cycle infection, the Th2 response to schisto-
some eggs would likely extend to sporozoite- and liver-
stages of plasmodia. In analogy, it has been demonstrated
that pre-treatment to tip the cytokine balance towards a
Th1 response significantly reduces the malaria parasite
load in the liver [22]. Thus, we suppose that the schisto-
somes would most likely affect the development of plas-
modial sporozoites via local interactions in the liver as
well as general immunomodulation.
No significant difference in CM rate or in survival was
seen when comparing P. berghei-infected and co-
infected mice 4 weeks post-S. mansoni infection. In con-
trast, concomitant infection seven weeks post-cercariae
injection caused a marked reduction in CM. The lack of
effect in the first case may be explained by the fact that
no mature worms are seen by four weeks after cercariae
injection. During the prepatent period of S. mansoni
infection, the first 4-5 weeks following exposure to cer-
cariae, the immune response is primarily Th1 in nature,
while an egg antigen-specific Th2 response is seen by
eight weeks post-infection [23]. IFNg production is
essential for CM development [2,17]. Accordingly, each
stage of schistosomal infection may affect the develop-
ment of CM in a different manner: we assume that the
initial Th1 response caused by the worms prevented any
ameliorating effect. During the patent phase of schisto-
somal infection (7 weeks after injection of cercariae), a
decreased rate of cerebral malaria was accompanied by
higher body temperature and less severe weight reduc-
tion. Analysis of cytokine levels revealed that the pre-
existing S. mansoni infection caused a Th2 shift, which
translated to the improved disease profile. This shift is
Figure 6 Parasitaemia (A) and survival (B) of mice administered
IPSE/alpha-1 by i.v. injection from day 4 before PbA infection
to day 7 post-infection. Control mice were injected with PBS.
*Significant difference in delay to death (p = 0.005, t-test). Shaded
areas denote the period of CM susceptibility and death.
Figure 7 Parasitaemia (A) and survival (B) of control mice (n =
10) and mice administered complete S. mansoni egg extract
(SmEA; n = 10) or egg extract from which IPSE/alpha-1 was
removed (SmEA ΔIPSE/alpha-1; n = 10), by i.v. injection, on
days 7 and 0 before PbA infection and days 3 and 6 post-
infection. Control mice were injected with PBS. *Parasitaemia was
slightly lower in mice treated with SmEA or SmEA ΔIPSE/alpha-1
compared to control mice, on days 7-10 post-infection (p < 0.05, t-
test). **A significant delay to death was seen between control and
treated mice (p < 0.05, t-test), but not between the treated groups
(p = 0.2, t-test). Shaded areas denote the period of CM susceptibility
and death.
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probably the result of an overall change in the balance
of cytokines, chemokines and adhesion molecules which
participate in the pathogenesis of CM. Therefore, an
estimate of a several factors (e.g. a sum of Th1 vs. Th2
cytokines) will better predict and correlate to the clinical
situation.
Additional cytokine analysis 4 weeks after S. mansoni
infection may demonstrate that the Th1 to Th2 shift
has not yet occurred. However, at this stage eggs are
not yet deposited. As mature egg, deposition is the
major stimulus for the production of Th2 cytokines in
murine S. mansoni infection [24], this is the reason for
our experimental design. The effect of co-infection on
the rate of CM was reduced when mice were injected
with a lower number of cercariae (50 vs.100), presum-
ably because of the less pronounced immune response
expected to have been elicited upon helminth infection.
Egg antigens are crucial in the pathology caused by
schistosomes [10,25]. In an established S. mansoni infec-
tion, egg-laying by the adult female worms causes a Th2
shift in the host immune response. SmEA is a complex
mixture of both structural and secretory egg antigens, the
latter of which are thought to react primarily with host
immune cells [26]. IPSE/alpha-1, a secretory glycoprotein
present only in mature eggs, is a general activator of both
human and murine basophils, triggering their degranula-
tion and IL-4 production as well as the release of IL-13
and histamine [12,15]. Depletion of IPSE/alpha-1 from
SmEA completely abrogates the SmEA-induced basophil
activation [12]. The immunogenicity of IPSE/alpha-1 is
due in part to the presence of glycans that carry one or
more Lewis X motifs, which, in the context of glycan
conjugates, induce production of Th2-associated media-
tors such as IL-10 and prostaglandin E2 [8]. Egg glycoli-
pid and glycoprotein epitopes found in both adult and
larval schistosomes are the predominant targets of the
humoral immune response in schistosomiasis [8]. The
activity of IPSE/alpha-1 is independent of basophil pre-
conditioning due to prior infections, and IL-4 production
can be induced in basophils in the liver, a major site of S.
mansoni egg deposition [27].
In our experiments, injection of IPSE/alpha-1 caused a
consistent delay in mouse death compared to non-trea-
ted mice, and a slight reduction in parasitaemia during
the first week of infection (p < 0.05). In contrast to S.
mansoni infection, no significant reduction in CM was
induced by injection of SmEA or IPSE/alpha1. Delay in
death, however, was pronounced upon injection of
SmEA, an effect which was reduced upon injection of
SmEA ΔIPSE/alpha-1 suggesting a role of IPSE/alpha-1.
Whether the prolonged survival of the P. berghei-S.
mansoni co-infected mice is due an anti-inflammatory
effect of IPSE/alpha-1-induced IL-4 (and IL-13) remains
to be determined. Nevertheless, this is an obvious
assumption, because apart from the direct polarization
of naïve T helper cells towards the Th2 phenotype, IL-4
has been shown to have a variety of anti-inflammatory
effects, such as inhibition of the LPS-induced release of
IL- 6, TNF, and IL1-b from monocytes [28], inhibition
of Th17-development [29] and together with IL-13 the
alternative activation of macrophages [30]. The observa-
tion that schistosome infection was superior to adminis-
tration of SmEA or IPSE/alpha-1 in preventing CM may
be explained by the continuous flow of egg antigens
during infection versus bolus application in the experi-
mental set-up and/or additional immunomodulatory fac-
tors released during active infection.
It should be emphasized that the result of infection in
a malaria-endemic area has a complex pattern due to
the variety of pathogens and the genetic variability of
the population. Despite this complexity, various investi-
gations have provided clues regarding the effect of con-
comitant helminthic infection on the course of malaria.
Observations in Thailand showed that co-infection with
intestinal helminths increased P. falciparum incidence
two-fold but decreased CM by 64% [31]. Schistosoma
haematobium infection was shown to reduce malaria
severity by increasing Th2 responses in P. falciparum-
infected children [32]; a recent ex-vivo study indicates
that helminth infections cause an increase in IL-10 but
no change in TNF [33], indicating suppression of pro-
inflammatory responses. Age infection profiles indicate
that school-age children are at the highest risk of co-
infection [34]; underlying schistosomiasis was associated
with protection against clinical falciparum malaria in
children under the age of 9 [35]. The effects of schisto-
somal infection were shown to be dependant on egg
load as well as age. Plasmodial levels in children with
light egg loads were lower when compared to children
with no schistosomal infection [35], while synergy was
observed in the case of high egg loads [36]. In mice,
existing S. mansoni infection interfered with attempts to
vaccinate against BCG [37] or HIV components [38].
Intestinal helminths have also been associated with pro-
tection from immunopathology. Nacher et al [39] indi-
cate protection from CM in human infection with
intestinal helminths. In a murine model, CBA/J mice
inoculated with Brugia pahangi developed a Th2
immune response, and, as a result, a lower rate of CM
following P. berghei injection [40]. In contrast, Bejon et
al [20] could not demonstrate an effect of intestinal hel-
minths on P. falciparum infection. It should be noted
that although these studies addressed patient exposure
to both Plasmodium and helminths, additional infec-
tions, a factor shown by murine models to be possibly
significant [41], was not investigated.
The effect of co-infections (schistosomes, hookworms,
and plasmodia) on anaemia should also be considered in
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view of competition between haematopoietic and immu-
nological compensations [42]. In addition, the concen-
tration of free haem, which is also affected by the
activity of these parasites, is related to the expression of
haem oxygenase, which prevents CM [43]. Notably there
can be significant changes in the vasculature induced by
schistosome infection including the development of col-
lateral circulation, the development of portal hyperten-
sion and hepato- and splenomegaly. All may have
important consequences for blood flow and for malaria
parasite distribution in concomitantly infected hosts.
The impact of schistosome infection on anaemia may
also be important. Red cell production dynamics and
the balance between mature erythrocytes and reticulo-
cytes may have been altered by the presence of adult
erythrocyteconsuming schistosomes.
Conclusions
The results of this research demonstrate that a preexist-
ing schistosome infection may drastically affect the out-
come of Plasmodium infection. Protection from CM
appears to be a function of S. mansoni parasite load. As
mentioned, microbial and parasitic infections in malaria-
endemic areas are not controlled and it is likely that
many persons are infected by more than one parasite
species (including helminths). Presence or absence of a
pre-existing infection may explain why certain indivi-
duals develop cerebral malaria while others exhibit
minor symptoms only. The presence of multiple parasi-
tic infections in patients from endemic areas should,
therefore, be carefully noted in future clinical trials, and
in the development of standard treatment protocols for
malaria infection.
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